Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aziz Zaanan

Showing results (81-90 of 128) with videos related to

Pageof 13
Sort By:
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|July 29, 2025
FOLFIRINOX or FOLFOX for locally advanced or metastatic small bowel adenocarcinoma: PRODIGE 86 - FFCD-GONO - ENGIC 02 - FOLFIRINOX SBA phase II randomized trialThomas Aparicio, Anthony Turpin, Aziz Zaanan, et al.
Bulletin Du Cancer|January 31, 2008
[Clinical and molecular consequences of microsatellite instability in human cancers]Richard Hamelin, Alexandra Chalastanis, Chrystelle Colas, et al.
Nature Communications|July 24, 2025
Longitudinal circulating tumor DNA analysis during treatment of locally advanced resectable gastric or gastroesophageal junction adenocarcinoma: the PLAGAST prospective biomarker studyAziz Zaanan, Audrey Didelot, Chloé Broudin, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|November 30, 2015
Prognostic value of health-related quality of life in patients with metastatic pancreatic adenocarcinoma: a random forest methodologyMomar Diouf, Thomas Filleron, Anne-Laure Pointet, et al.
European Journal of Cancer (Oxford, England : 1990)|December 3, 2014
Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: an AGEO randomised phase II study (FIRGEM)Isabelle Trouilloud, Anne-Claire Dupont-Gossard, David Malka, et al.
European Journal of Cancer (Oxford, England : 1990)|December 20, 2020
Prognostic variables in low and high risk stage III colon cancers treated in two adjuvant chemotherapy trialsFrank A Sinicrope, Sakti Chakrabarti, Pierre Laurent-Puig, et al.
Analytical Chemistry|March 3, 2018
BIABooster: Online DNA Concentration and Size Profiling with a Limit of Detection of 10 fg/μL and Application to High-Sensitivity Characterization of Circulating Cell-Free DNAComtet-Louis Andriamanampisoa, Aurélien Bancaud, Audrey Boutonnet-Rodat, et al.
Investigational New Drugs|June 22, 2026
Evaluating pegenzileukin (SAR444245/THOR-707) in combination with pembrolizumab or cetuximab in advanced metastatic gastrointestinal cancer: the PEGATHOR phase 2 studyWilliam P Harris, Pilar García-Alfonso, Jean Phillipe Metges, et al.
JAMA Oncology|June 18, 2025
Early ctDNA and Survival in Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors: A Secondary Analysis of the SAMCO-PRODIGE 54 Randomized Clinical TrialJulien Taïeb, Francesco Giulio Sullo, Aurélie Lecanu, et al.
Cancers|November 13, 2021
Targeting HGF/c-Met Axis Decreases Circulating Regulatory T Cells Accumulation in Gastric Cancer PatientsJuliette Palle, Laure Hirsch, Alexandra Lapeyre-Prost, et al.
Pageof 13

Showing results (81-90 of 128) with videos related to

Sort By:
Pageof 13
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|July 29, 2025
FOLFIRINOX or FOLFOX for locally advanced or metastatic small bowel adenocarcinoma: PRODIGE 86 - FFCD-GONO - ENGIC 02 - FOLFIRINOX SBA phase II randomized trialThomas Aparicio, Anthony Turpin, Aziz Zaanan, et al.
Bulletin Du Cancer|January 31, 2008
[Clinical and molecular consequences of microsatellite instability in human cancers]Richard Hamelin, Alexandra Chalastanis, Chrystelle Colas, et al.
Nature Communications|July 24, 2025
Longitudinal circulating tumor DNA analysis during treatment of locally advanced resectable gastric or gastroesophageal junction adenocarcinoma: the PLAGAST prospective biomarker studyAziz Zaanan, Audrey Didelot, Chloé Broudin, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|November 30, 2015
Prognostic value of health-related quality of life in patients with metastatic pancreatic adenocarcinoma: a random forest methodologyMomar Diouf, Thomas Filleron, Anne-Laure Pointet, et al.
European Journal of Cancer (Oxford, England : 1990)|December 3, 2014
Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: an AGEO randomised phase II study (FIRGEM)Isabelle Trouilloud, Anne-Claire Dupont-Gossard, David Malka, et al.
European Journal of Cancer (Oxford, England : 1990)|December 20, 2020
Prognostic variables in low and high risk stage III colon cancers treated in two adjuvant chemotherapy trialsFrank A Sinicrope, Sakti Chakrabarti, Pierre Laurent-Puig, et al.
Analytical Chemistry|March 3, 2018
BIABooster: Online DNA Concentration and Size Profiling with a Limit of Detection of 10 fg/μL and Application to High-Sensitivity Characterization of Circulating Cell-Free DNAComtet-Louis Andriamanampisoa, Aurélien Bancaud, Audrey Boutonnet-Rodat, et al.
Investigational New Drugs|June 22, 2026
Evaluating pegenzileukin (SAR444245/THOR-707) in combination with pembrolizumab or cetuximab in advanced metastatic gastrointestinal cancer: the PEGATHOR phase 2 studyWilliam P Harris, Pilar García-Alfonso, Jean Phillipe Metges, et al.
JAMA Oncology|June 18, 2025
Early ctDNA and Survival in Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors: A Secondary Analysis of the SAMCO-PRODIGE 54 Randomized Clinical TrialJulien Taïeb, Francesco Giulio Sullo, Aurélie Lecanu, et al.
Cancers|November 13, 2021
Targeting HGF/c-Met Axis Decreases Circulating Regulatory T Cells Accumulation in Gastric Cancer PatientsJuliette Palle, Laure Hirsch, Alexandra Lapeyre-Prost, et al.
Pageof 13